Despite major interest in this pathway for cancer drug discovery, no drugs have yet been approved that act specifically against PI3K or its downstream regulator, AKT. However, several drugs that ...

Promising therapies for platinum-resistant ovarian cancer produced mixed results in separate trials. The AKT inhibitor ...

A new review article highlights the transformative role of circular RNA (circRNA) in cancer, revealing its potential as both ...

Researchers from SRM Institute of Science and Technology, led by Dr. KN Aruljothi, have published a study in ExRNA ...

The company’s head of oncology, Dave Fredrickson, said the approval of Truqap “reinforces the important role of the PI3K/AKT pathway in HR-positive breast cancer and the critical need to test ...

The laboratory is studying small molecules that selectively inhibit the components of RAS-RAF-MEK-ERK and PI3K-AKT-mTOR pathways. These compounds are being used as reagents to define the role of these ...

A new review article highlights the transformative role of circular RNA (circRNA) in cancer, revealing its potential as both a key player in tumor biology and a promising avenue for future therapies.

Plectin drives hepatocellular carcinoma progression and metastasis through cytoskeletal reorganization and oncogenic signaling, making it a promising therapeutic target for overcoming therapy ...